Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer

Trial Profile

Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Docetaxel; Gemcitabine
  • Indications Bladder cancer; Carcinoma; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Feb 2018 Results (n=20) of expansion cohort assessing safety and efficacy presented at the 2018 Genitourinary Cancers Symposium
    • 27 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top